vasilip 20mg potahovaná tableta - leitarniðurstöður

Evrópusambandið - íslenska - EMA (European Medicines Agency)

protopic

leo pharma a/s - takrólímus - dermatitis, atópísk - aðrar húðsjúkdómar - flare treatmentadults and adolescents (16 years of age and above)treatment of moderate to severe atopic dermatitis in adults who are not adequately responsive to or are intolerant of conventional therapies such as topical corticosteroids. children (two years of age and above)treatment of moderate to severe atopic dermatitis in children (two years of age and above) who failed to respond adequately to conventional therapies such as topical corticosteroids. maintenance treatmentmaintenance treatment of moderate to severe atopic dermatitis for the prevention of flares and the prolongation of flare-free intervals in patients experiencing a high frequency of disease exacerbations (i. koma fjórir eða meira sinnum á ári) sem hafa haft fyrstu viðbrögð við sex vikur meðferð tvisvar á dag takrólímus smyrslið (sár ruddi, næstum ruddi eða dálítið áhrifum).

Evrópusambandið - íslenska - EMA (European Medicines Agency)

qdenga

takeda gmbh - dengue virus, serotype 2, expressing dengue virus, serotype 1, surface proteins, live, attenuated, dengue virus, serotype 2, expressing dengue virus, serotype 3, surface proteins, live, attenuated, dengue virus, serotype 2, expressing dengue virus, serotype 4, surface proteins, live, attenuated, dengue virus, serotype 2, live, attenuated - fjölmörgum - bóluefni - qdenga is indicated for the prevention of dengue disease in individuals from 4 years of age. the use of qdenga should be in accordance with official recommendations.